China Health Care Firm Collaborates With Domestic Insurer
This article was originally published in PharmAsia News
Ping An Insurance Group subsidiary Ping An Trust & Investment has acquired stakes in Ciming Health Checkup Group, the first such cooperation between an insurer and health care company in China. The firms did not disclose the investment amount but analysts estimate the share proportion taken up by Ping An to be no more than 15 percent and the investment capital less than 20 million yuan. Ciming's president explained that both parties are focusing more on the mutual business benefits than on funds; Ping An may reduce fraudulent claims risks by collaborating with a health care organization, while Ciming can expand its clientele base with policyholders recommended by the insurer. (Click here for more - Chinese Language)
You may also be interested in...
Avadim Health argues National Advertising Division expects substantiation for its homeopathic topical claims at the same level FDA requires for NDAs. NAD also said although FTC’s competent, reliable scientific evidence standard is “flexible” to some degree, pain claims are held to a more rigid standard.
With Roche's oral spinal muscular atrophy therapy Evrysdi off to a strong start after its recent US launch, Novartis is switching its priorities for rival RNA-splicing drug branaplam and putting it into a Phase IIb trial for Huntington's disease.
The FDA has asked the company for more information to support its PoNS therapy for multiple sclerosis patients with gait deficit, including an additional analysis of clinical data and labeling modifications.